Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2023

Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. Current treatment varies by subtype, although rituximab in combination with chemotherapy remains a mainstay of treatment across NHL subtypes. The approval of chimeric antigen receptor (CAR) T-cell therapies and new branded drugs has rapidly expanded the treatment armamentarium, especially for diffuse large B-cell lymphoma (DLBCL). Recent DLBCL market entrants include Zynlonta (ADC Therapeutics), Monjuvi (MorphoSys / Incyte), Xpovio (Karyopharm), Polivy (Roche / Genentech), and the CAR T-cell therapy Breyanzi (Bristol Myers Squibb). Meanwhile, CAR T-cell therapies (Yescarta and Tecartus [Gilead / Kite Pharma], Kymriah [Novartis]) and other novel targeted agents (Lunsumio [Roche], Tazverik [Epizyme], and Brukinsa [BeiGene]) are transforming the treatment of follicular lymphoma and mantle cell lymphoma.

Questions answered

• What is the patient share of recent market entrants such as the bispecific antibody Lunsumio in the United States, according to surveyed hematologist-oncologists?
• How does physician prescribing of current treatments vary based on genetic mutations and transplant eligibility / ineligibility criteria for NHL / CLL?
• How do drug-treatment rates vary across key B-cell NHL / CLL subtypes by line of therapy?
• What is the patient share of key therapies and regimens used to treat newly diagnosed and relapsed / refractory NHL / CLL subtypes?
• What are the key drivers and obstacles determining current prescribing patterns in NHL / CLL?
• What are the clinical characteristics that physicians consider when prescribing CAR T-cell therapies for NHL / CLL by subtype and line?

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States.

Primary research: Survey of 101 U.S. hematologist-oncologists.

Key drugs covered: Aliqopa, Arzerra, Breyanzi, Brukinsa, Calquence, Copiktra, Gazyva, Imbruvica, Lunsumio, Kymriah, Monjuvi, Polivy, Revlimid, Rituximab, Tazverik, Tecartus, Velcade, Venclexta, Xpovio, Yescarta, Zydelig, Zynlonta